Literature DB >> 33414479

Apoptosis inhibitor of macrophage (AIM) contributes to IL-10-induced anti-inflammatory response through inhibition of inflammasome activation.

Tae-Hyun Kim1, Kyungwon Yang1,2, Minsuk Kim2,3, Hee-Sun Kim4, Jihee Lee Kang5,6.   

Abstract

Apoptosis inhibitor of macrophage (AIM) modulates the signaling in inflammatory responses, including infection, cancer, or other immune diseases. Recent studies suggest that like interleukin-10 (IL-10), AIM is involved in alternatively activated (M2) macrophage polarization. We aimed to understand whether and how AIM is involved in IL-10-induced inhibition of inflammasome activation and resolution of inflammation. First, we demonstrated that IL-10 induced increases in mRNA and protein expression of AIM in murine bone marrow-derived macrophages (BMDM). In addition, genetic and pharmacologic inhibition of STAT3 (signal transducer and activator of transcription 3) reduced IL-10-induced AIM expression. We also found that IL-10-induced STAT3 activity enhanced the AIM promoter activity by directly binding the promoter of the AIM gene. Additionally, reduction of LPS/adenosine triphosphate (ATP)-induced IL-1β production and caspase-1 activation by IL-10 was reversed in BMDM from AIM-/- mice. Treatment of BMDM from both wild type (WT) and IL-10-/- mice with recombinant AIM showed the inhibitory effects on IL-1β and IL-18 production and caspase-1 activation. Endogenous and exogenous AIM inhibited apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC) speck formation. In LPS-induced acute peritonitis, inhibition of IL-1β and IL-18 production in peritoneal lavage fluid (PLF) and serum, reduction of caspase-1 activation in peritoneal macrophages, and reduction of numbers of neutrophils and peritoneal macrophages in PLF by administration of IL-10 were not evident in AIM-/- mice. Our in vitro and in vivo data reveal a novel role of AIM in the inhibition of inflammasome-mediated caspase-1 activation and IL-1β and IL-18 production.

Entities:  

Year:  2021        PMID: 33414479      PMCID: PMC7791024          DOI: 10.1038/s41419-020-03332-w

Source DB:  PubMed          Journal:  Cell Death Dis            Impact factor:   8.469


  48 in total

Review 1.  The inflammasomes.

Authors:  Kate Schroder; Jurg Tschopp
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Mitochondrial ROS fuel the inflammasome.

Authors:  Matthew T Sorbara; Stephen E Girardin
Journal:  Cell Res       Date:  2011-02-01       Impact factor: 25.617

3.  Tr1 Cells, but Not Foxp3+ Regulatory T Cells, Suppress NLRP3 Inflammasome Activation via an IL-10-Dependent Mechanism.

Authors:  Yu Yao; Jens Vent-Schmidt; Matthew D McGeough; May Wong; Hal M Hoffman; Theodore S Steiner; Megan K Levings
Journal:  J Immunol       Date:  2015-06-08       Impact factor: 5.422

4.  Macrophage-derived AIM is endocytosed into adipocytes and decreases lipid droplets via inhibition of fatty acid synthase activity.

Authors:  Jun Kurokawa; Satoko Arai; Katsuhiko Nakashima; Hiromichi Nagano; Akemi Nishijima; Keishi Miyata; Rui Ose; Mayumi Mori; Naoto Kubota; Takashi Kadowaki; Yuichi Oike; Hisashi Koga; Maria Febbraio; Toshihiko Iwanaga; Toru Miyazaki
Journal:  Cell Metab       Date:  2010-06-09       Impact factor: 27.287

5.  Endogenous IL-10 protects mice from death during septic peritonitis.

Authors:  T van der Poll; A Marchant; W A Buurman; L Berman; C V Keogh; D D Lazarus; L Nguyen; M Goldman; L L Moldawer; S F Lowry
Journal:  J Immunol       Date:  1995-12-01       Impact factor: 5.422

6.  Cutting edge: TNF-alpha mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation.

Authors:  Luigi Franchi; Tatjana Eigenbrod; Gabriel Núñez
Journal:  J Immunol       Date:  2009-06-19       Impact factor: 5.422

Review 7.  Reactive oxygen species at the crossroads of inflammasome and inflammation.

Authors:  Anantha Harijith; David L Ebenezer; Viswanathan Natarajan
Journal:  Front Physiol       Date:  2014-09-29       Impact factor: 4.566

8.  Interleukin 10 protects mice from lethal endotoxemia.

Authors:  M Howard; T Muchamuel; S Andrade; S Menon
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

9.  Extracellular ATP Activates the NLRP3 Inflammasome and Is an Early Danger Signal of Skin Allograft Rejection.

Authors:  Joaquín Amores-Iniesta; Maria Barberà-Cremades; Carlos M Martínez; José A Pons; Beatriz Revilla-Nuin; Laura Martínez-Alarcón; Francesco Di Virgilio; Pascual Parrilla; Alberto Baroja-Mazo; Pablo Pelegrín
Journal:  Cell Rep       Date:  2017-12-19       Impact factor: 9.423

10.  Cardamonin from a medicinal herb protects against LPS-induced septic shock by suppressing NLRP3 inflammasome.

Authors:  Zhilei Wang; Guang Xu; Yuan Gao; Xiaoyan Zhan; Nan Qin; Shubin Fu; Ruisheng Li; Ming Niu; Jiabo Wang; Youping Liu; Xiaohe Xiao; Zhaofang Bai
Journal:  Acta Pharm Sin B       Date:  2019-02-14       Impact factor: 11.413

View more
  4 in total

Review 1.  The Macrophage-Osteoclast Axis in Osteoimmunity and Osteo-Related Diseases.

Authors:  Yao Yao; Xiaoyu Cai; Fujia Ren; Yiqing Ye; Fengmei Wang; Caihong Zheng; Ying Qian; Meng Zhang
Journal:  Front Immunol       Date:  2021-03-31       Impact factor: 7.561

2.  Effects of synthetic silymarin-PLGA nanoparticles on M2 polarization and inflammatory cytokines in LPS-treated murine peritoneal macrophages.

Authors:  Mojgan Azadpour; Mohammad Morad Farajollahi; Hassan Dariushnejad; Ali Mohammad Varzi; Amir Varezardi; Mitra Barati
Journal:  Iran J Basic Med Sci       Date:  2021-10       Impact factor: 2.699

Review 3.  TI: NLRP3 Inflammasome-Dependent Pyroptosis in CNS Trauma: A Potential Therapeutic Target.

Authors:  Conghui Zhou; Jinfeng Zheng; Yunpeng Fan; Junsong Wu
Journal:  Front Cell Dev Biol       Date:  2022-02-02

Review 4.  Approaches for Controlling Antibody-Mediated Allograft Rejection Through Targeting B Cells.

Authors:  Yoshiko Matsuda; Takeshi Watanabe; Xiao-Kang Li
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.